Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolasetron triple antiemetic prophylaxis for highly emetogenic chemotherapy
ChiCTR2500101930Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolasetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Complete response rate during overall phase. Planned start May 2025; status: not yet recruiting.
02
Drugs
dolasetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2500101930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101930.